Premie steroid study: could a common drug raise blood pressure years later?

NCT ID NCT05451264

Completed Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows up on 52 children, now aged 7 to 13, who were born very prematurely and received either hydrocortisone or a placebo in the PREMILOC trial. Researchers are measuring their blood pressure, pulse wave velocity, and other heart-related markers to see if the steroid affected their cardiovascular health. The goal is to understand long-term risks, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: hydrocortisone
What this could lead to: If it works, this could help doctors understand whether hydrocortisone given to premature babies raises their risk of high blood pressure later in life.
What could go wrong: This is a small, observational follow-up study, not a new treatment trial. It can only show a link, not prove cause and effect, and results may not apply to all premature infants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFANT, PREMATURE, DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Infant, Premature, Diseases

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFANT, PREMATURE, DISEASES

Contacts and locations

Locations

Robert Debre Hospital

Paris, 75019, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.